Avidian Wealth Solutions LLC Takes Position in Eterna Therapeutics Inc. (NASDAQ:ERNA)

Avidian Wealth Solutions LLC bought a new position in Eterna Therapeutics Inc. (NASDAQ:ERNAFree Report) in the first quarter, according to its most recent filing with the SEC. The firm bought 14,798 shares of the company’s stock, valued at approximately $36,000. Avidian Wealth Solutions LLC owned approximately 0.27% of Eterna Therapeutics as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Lake Street Advisors Group LLC purchased a new position in Eterna Therapeutics in the 4th quarter worth $933,000. Sippican Capital Advisors raised its stake in shares of Eterna Therapeutics by 92.3% in the fourth quarter. Sippican Capital Advisors now owns 54,050 shares of the company’s stock worth $97,000 after purchasing an additional 25,950 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Eterna Therapeutics by 30.6% during the third quarter. Vanguard Group Inc. now owns 24,898 shares of the company’s stock worth $54,000 after purchasing an additional 5,830 shares during the period. Hedge funds and other institutional investors own 70.55% of the company’s stock.

Eterna Therapeutics Stock Performance

NASDAQ:ERNA traded down $0.05 during midday trading on Wednesday, hitting $1.78. The company’s stock had a trading volume of 2,137 shares, compared to its average volume of 8,382. Eterna Therapeutics Inc. has a fifty-two week low of $0.84 and a fifty-two week high of $2.99. The company has a debt-to-equity ratio of 3.03, a current ratio of 0.79 and a quick ratio of 0.79. The firm has a market cap of $9.63 million, a P/E ratio of -0.42 and a beta of 4.49. The firm’s 50 day moving average is $1.94 and its 200-day moving average is $1.92.

Eterna Therapeutics (NASDAQ:ERNAGet Free Report) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($1.23) earnings per share (EPS) for the quarter. The firm had revenue of $0.05 million during the quarter.

Eterna Therapeutics Profile

(Free Report)

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.

Featured Articles

Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.